Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00183742 · ClinicalTrials.gov registry record · Phase 1

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

A Phase 1 study, sponsored by University of Southern California.

Completed
Registry status
Phase 1
Development phase
35
Enrollment target

NCT00183742: Completed Phase 1 study, sponsored by University of Southern California.

NCT00183742 is a Phase 1 study that has completed, run by University of Southern California. The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00183742, a Phase 1 study, has completed, sponsored by University of Southern California.

COMPLETED
Registry status
Phase 1
Development phase
35 participants
Enrollment target

Study Summary

This study is for patients with advanced cancer that has failed treatment with conventional therapy or for which no standard treatment exists. The purpose of this study is to determine the highest dose that can be given of 2 chemotherapy drugs, docetaxel (also called Taxotere) and liposomal doxorubicin (also called Doxil), when given together and to determine the side effects of this combination. Both Taxotere and Doxil are chemotherapy drugs that can decrease the size of several different tumors. Taxotere is approved by the Food and Drug Administration (FDA) for the treatment of breast and lung cancers, and Doxil is approved for the treatment of ovarian cancer.

Interventions

  • DRUG liposomal doxorubicin and docetaxel

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2000-12
Est. Completion 2006-05
Phase Phase 1
University of Southern California

617 total trials

What the finished NCT00183742 record still lists

NCT00183742 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).

The record links to 0 conditions, and to 1 intervention - of which liposomal doxorubicin and docetaxel is the first listed.

NCT00183742 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00183742 about?

NCT00183742 is a clinical study titled "Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)". This study is for patients with advanced cancer that has failed treatment with conventional therapy or for which no standard treatment exists. The purpose of this study is to determine the highest dose that can be given of 2 chemotherapy drugs, docetaxel (also called Taxotere) and liposomal doxorubi...

What is the current status of trial NCT00183742?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2000-12. Estimated completion is 2006-05.

What interventions are being tested in trial NCT00183742?

The interventions under investigation include: liposomal doxorubicin and docetaxel (DRUG).

Who is sponsoring clinical trial NCT00183742?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00183742's enrollment target sits among peer trials

35 1258th of 2000 higher than 728 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00183742, the US trial registry maintained by the National Library of Medicine. NCT00183742 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.